Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The US Food and Drug Administration (FDA) has identified approximately 20 drugs at risk of shortage due to the ongoing coronavirus outbreak.

These drugs either source all main ingredients from China or are finished in the country, noted Reuters.

When the agency contacted manufacturers of the identified drugs, none reported an expected shortage due to the epidemic.

FDA spokeswoman Stephanie Caccomo was quoted as saying: “We have been in contact with those firms to understand if they face any drug shortage risks due to the outbreak. None of these firms has reported any shortage to date.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“We will continue to remain in contact with the manufacturers so that we can best help mitigate any potential issues in the future.”

Since 24 January, the agency also notified more than 180 companies to alert the FDA in case of any expected shortages. Also, the FDA asked the manufacturers to assess their entire supply chain, said CNBC.

In a separate development, US President Donald Trump’s administration is seeking $2.5bn from Congress to combat the coronavirus.

According to the White House, more than $1bn of the funds would go towards developing a vaccine, with the remaining allocated for therapeutics and stockpiling of protective equipment such as masks.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact